 Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 3 | 1 | 4 | | 2009 | 3 | 0 | 3 | | 2010 | 4 | 3 | 7 | | 2011 | 3 | 1 | 4 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 3 | 5 | | 2014 | 3 | 2 | 5 | | 2015 | 2 | 5 | 7 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 2 | 3 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Kim SM, DeFazio JR, Hyoju SK, Sangani K, Keskey R, Krezalek MA, Khodarev NN, Sangwan N, Christley S, Harris KG, Malik A, Zaborin A, Bouziat R, Ranoa DR, Wiegerinck M, Ernest JD, Shakhsheer BA, Fleming ID, Weichselbaum RR, Antonopoulos DA, Gilbert JA, Barreiro LB, Zaborina O, Jabri B, Alverdy JC. Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nat Commun. 2020 05 11; 11(1):2354.
-
Ali M, Shahin SM, Sabri NA, Al-Hendy A, Yang Q. Activation of ß-Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids. J Clin Endocrinol Metab. 2020 04 01; 105(4).
-
Yu Y, Ran D, Jiang J, Pan T, Dan Y, Tang Q, Li W, Zhang L, Gan L, Gan Z. Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2. Bioorg Med Chem Lett. 2019 08 15; 29(16):2136-2140.
-
Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540.
-
Singh H, Wray N, Schappi JM, Rasenick MM. Disruption of lipid-raft localized Gas/tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds. Neuropsychopharmacology. 2018 06; 43(7):1481-1491.
-
Godley LA. Mutant RUNX1 and histone tales. Blood. 2017 11 16; 130(20):2156-2157.
-
Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017 12; 7(12):1450-1463.
-
Collins CM, Ellis JA, Holaska JM. MAPK signaling pathways and HDAC3 activity are disrupted during differentiation of emerin-null myogenic progenitor cells. Dis Model Mech. 2017 04 01; 10(4):385-397.
-
Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Res. 2017 01 15; 77(2):470-481.
-
Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|